Back to today’s briefing

Story perspectives

AstraZeneca Partners with Algen for $555M AI Therapies

10/6/2025

41 4

Summary

Story summary

Algen Biotechnologies and AstraZeneca will develop AI-driven therapies using AlgenBrain, in a deal up to $555 million.
AstraZeneca gains exclusive rights to develop and commercialize therapies for immune-system disorders, aligned with its goal of $80 billion in 2030 sales.
Algen will receive upfront payments and milestones based on program progress.
The partnership does not involve AstraZeneca acquiring equity in Algen.

1 of 1

Story summary

Algen Biotechnologies and AstraZeneca will develop AI-driven therapies using AlgenBrain, in a deal up to $555 million.
AstraZeneca gains exclusive rights to develop and commercialize therapies for immune-system disorders, aligned with its goal of $80 billion in 2030 sales.
Algen will receive upfront payments and milestones based on program progress.
The partnership does not involve AstraZeneca acquiring equity in Algen.